Cue Biopharma (NASDAQ:CUE) CEO Shao-Lee Lin Sells 11,087 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 11,087 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $27.55, for a total value of $305,446.85. Following the sale, the chief executive officer owned 694,908 shares in the company, valued at approximately $19,144,715.40. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96.
• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Stock Performance

Cue Biopharma stock traded down $0.97 during midday trading on Wednesday, reaching $18.60. 244,958 shares of the stock were exchanged, compared to its average volume of 475,854. The company’s fifty day moving average is $27.73 and its 200-day moving average is $72.25. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The firm had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. As a group, analysts expect that Cue Biopharma, Inc. will post -21.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

CUE has been the topic of several research analyst reports. Zacks Research upgraded shares of Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. Weiss Ratings lowered shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. B. Riley Financial started coverage on shares of Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 target price for the company. Finally, Wall Street Zen cut shares of Cue Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cue Biopharma currently has an average rating of “Hold” and an average price target of $83.00.

Institutional Investors Weigh In On Cue Biopharma

Several hedge funds have recently added to or reduced their stakes in CUE. Northwestern Mutual Wealth Management Co. bought a new stake in Cue Biopharma in the 2nd quarter worth approximately $83,000. Bank of America Corp DE bought a new position in Cue Biopharma during the second quarter valued at approximately $219,000. Seven Fleet Capital Management LP bought a new position in Cue Biopharma during the second quarter valued at approximately $338,000. Persistent Asset Partners Ltd purchased a new position in shares of Cue Biopharma during the second quarter worth approximately $389,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Cue Biopharma during the second quarter worth approximately $722,000. Institutional investors own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.